Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study. (PubMed, Sage Open Chronic Dis) - Sep 24, 2026 - "In CD, ustekinumab had the highest escalation rate (69.1%), compared with infliximab (16.4%), adalimumab (21.2%), and vedolizumab (23.2%). For UC, adalimumab was most frequently escalated (21.8%), followed by tofacitinib (19.5%), ustekinumab (17.9%), and infliximab (10.0%)...Dose escalation is a common occurrence in IBD maintenance therapy, with substantial variation across treatment agents and patient profiles. These findings emphasize the importance of individualized treatment strategies to improve long-term disease control."
Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
|
|
Dahye Ryu; Hae Sun Suh; Hyun Jin Han; Junghyun Na; Seoyeon Choi; Young Mi Park
|